Literature DB >> 25258455

Assessment of Foetal DNA in Maternal Blood - A Useful Tool in the Hands of Prenatal Specialists.

K O Kagan1, M Hoopmann1, P Kozlowski2.   

Abstract

Over the last few years, first trimester screening between 11+ and 13+ weeks of gestation has become one of the most important ultrasound examinations in pregnancy, as it allows physicians to predict several pregnancy complications including pre-eclampsia or pre-term birth. Screening for trisomies 21/18 and 13 using maternal and gestational age, foetal nuchal translucency, and maternal serum biochemistry was formerly the main reason for first trimester screening. However, today this is only one part of the overall examination. In the near future, the analysis of foetal DNA obtained from maternal blood will be used to supplement first trimester screening for aneuploidy or even replace current screening methods. In this review we show how prenatal medicine specialists can use foetal DNA analysis.

Entities:  

Keywords:  first trimester screening; foetal DNA; trisomy; ultrasound

Year:  2012        PMID: 25258455      PMCID: PMC4168339          DOI: 10.1055/s-0032-1327960

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  36 in total

1.  Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.

Authors:  Emmanuel Bujold; Stéphanie Roberge; Yves Lacasse; Marc Bureau; François Audibert; Sylvie Marcoux; Jean-Claude Forest; Yves Giguère
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

2.  Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes.

Authors:  Francesca Romana Grati; Andrea Barlocco; Beatrice Grimi; Silvia Milani; Giuditta Frascoli; Anna Maria Di Meco; Rosaria Liuti; Anna Trotta; Sara Chinetti; Francesca Dulcetti; Anna Maria Ruggeri; Simona De Toffol; Maurizio Clementi; Federico Maggi; Giuseppe Simoni
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

3.  A mixture model of nuchal translucency thickness in screening for chromosomal defects.

Authors:  D Wright; K O Kagan; F S Molina; A Gazzoni; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2008-04       Impact factor: 7.299

Review 4.  Turning the pyramid of prenatal care.

Authors:  Kypros H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2011-03-08       Impact factor: 2.587

5.  Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing.

Authors:  Diana W Bianchi; Lawrence D Platt; James D Goldberg; Alfred Z Abuhamad; Amy J Sehnert; Richard P Rava
Journal:  Obstet Gynecol       Date:  2012-05       Impact factor: 7.661

6.  Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.

Authors:  Rossa W K Chiu; Ranjit Akolekar; Yama W L Zheng; Tak Y Leung; Hao Sun; K C Allen Chan; Fiona M F Lun; Attie T J I Go; Elizabeth T Lau; William W K To; Wing C Leung; Rebecca Y K Tang; Sidney K C Au-Yeung; Helena Lam; Yu Y Kung; Xiuqing Zhang; John M G van Vugt; Ryoko Minekawa; Mary H Y Tang; Jun Wang; Cees B M Oudejans; Tze K Lau; Kypros H Nicolaides; Y M Dennis Lo
Journal:  BMJ       Date:  2011-01-11

7.  Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.

Authors:  K O Kagan; S Cicero; I Staboulidou; D Wright; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2009-03       Impact factor: 7.299

8.  Prospective validation of first-trimester combined screening for trisomy 21.

Authors:  K O Kagan; A Etchegaray; Y Zhou; D Wright; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2009-07       Impact factor: 7.299

9.  Individual risk of fetal loss following routine second trimester amniocentesis: a controlled study of 20,460 cases.

Authors:  P Kozlowski; A Knippel; R Stressig
Journal:  Ultraschall Med       Date:  2007-06-29       Impact factor: 6.548

10.  Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy.

Authors:  Andrew B Sparks; Eric T Wang; Craig A Struble; Wade Barrett; Renee Stokowski; Celeste McBride; Jacob Zahn; Kevin Lee; Naiping Shen; Jigna Doshi; Michel Sun; Jill Garrison; Jay Sandler; Desiree Hollemon; Patrick Pattee; Aoy Tomita-Mitchell; Michael Mitchell; John Stuelpnagel; Ken Song; Arnold Oliphant
Journal:  Prenat Diagn       Date:  2012-01-06       Impact factor: 3.050

View more
  3 in total

1.  Prevalence, Spectrum and Antibiotic Susceptibility of Bacterial and Candida Colonization between the 21st and 33rd Week of Gestation in Women with PPROM - 5 Years' Experience in 1 Perinatal Center.

Authors:  J Reinhard; N Sänger; L C Hanker; S Peiffer; J Yuan; V A J Kempf; F Louwen
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-01       Impact factor: 2.915

2.  Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21.

Authors:  K O Kagan; M Schmid; M Hoopmann; P Wagner; H Abele
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

3.  Biomarkers in women's cancers, gynecology, and obstetrics.

Authors:  Peter A Fasching; Gottfried E Konecny; Amanda B Spurdle
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.